aTyr Pharma マネジメント
マネジメント 基準チェック /44
現在、CEO に関する十分な情報がありません。
主要情報
Sanjay Shukla
最高経営責任者
US$1.3m
報酬総額
| CEO給与比率 | 43.2% |
| CEO在任期間 | 7yrs |
| CEOの所有権 | 0.2% |
| 経営陣の平均在職期間 | 5.9yrs |
| 取締役会の平均在任期間 | 15.1yrs |
経営陣の近況
Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$64m |
| Jun 30 2024 | n/a | n/a | -US$58m |
| Mar 31 2024 | n/a | n/a | -US$54m |
| Dec 31 2023 | US$1m | US$561k | -US$50m |
| Sep 30 2023 | n/a | n/a | -US$43m |
| Jun 30 2023 | n/a | n/a | -US$45m |
| Mar 31 2023 | n/a | n/a | -US$45m |
| Dec 31 2022 | US$2m | US$561k | -US$45m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$41m |
| Mar 31 2022 | n/a | n/a | -US$39m |
| Dec 31 2021 | US$2m | US$510k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$30m |
| Jun 30 2021 | n/a | n/a | -US$29m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$1m | US$470k | -US$16m |
| Sep 30 2020 | n/a | n/a | -US$17m |
| Jun 30 2020 | n/a | n/a | -US$16m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$664k | US$450k | -US$24m |
| Sep 30 2019 | n/a | n/a | -US$24m |
| Jun 30 2019 | n/a | n/a | -US$25m |
| Mar 31 2019 | n/a | n/a | -US$30m |
| Dec 31 2018 | US$1m | US$450k | -US$35m |
| Sep 30 2018 | n/a | n/a | -US$40m |
| Jun 30 2018 | n/a | n/a | -US$44m |
| Mar 31 2018 | n/a | n/a | -US$45m |
| Dec 31 2017 | US$2m | US$403k | -US$48m |
報酬と市場: Sanjayの 総報酬 ($USD 1.30M ) は、 US市場 ($USD 1.46M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Sanjayの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Sanjay Shukla (52 yo)
7yrs
在職期間
US$1,300,525
報酬
Dr. Sanjay S. Shukla, M.D. M.S. has been the Chief Executive Officer, President and Director at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. fro...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7yrs | US$1.30m | 0.16% $ 426.0k | |
| Chief Financial Officer | 6.3yrs | US$677.84k | 0.025% $ 65.0k | |
| General Counsel & Corporate Secretary | 10.1yrs | US$651.28k | 0.027% $ 69.5k | |
| Founder | no data | データなし | データなし | |
| Vice President of Technical Operations | less than a year | データなし | データなし | |
| Director of Investor Relations & Corporate Communications | no data | データなし | データなし | |
| Vice President of Corporate Development | 4.8yrs | データなし | データなし | |
| VP of Human Resource | 2.9yrs | データなし | データなし | |
| Vice President of Research | no data | データなし | データなし | |
| Executive Director of Biologics Development & Manufacturing | no data | データなし | データなし | |
| Scientific Consultant | 5.9yrs | US$717.31k | データなし |
5.9yrs
平均在職期間
62yo
平均年齢
経験豊富な経営陣: ATYRの経営陣は経験豊富で経験豊富です（平均在職期間は5.9年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| President | 7yrs | US$1.30m | 0.16% $ 426.0k | |
| Independent Director | 19.2yrs | US$120.84k | 0.024% $ 61.8k | |
| Independent Director | 19.2yrs | US$61.20k | 1.31% $ 3.4m | |
| Member of Scientific Advisory Board | 15.1yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 15.3yrs | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Chairman of the Board | 7.6yrs | US$92.20k | 0.067% $ 174.7k | |
| Member of Scientific Advisory Board | 15.2yrs | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 5.3yrs | US$68.88k | 0.0072% $ 18.7k |
15.1yrs
平均在職期間
67yo
平均年齢
経験豊富なボード: ATYRの 取締役会 は経験豊富で 経験豊富 です ( 15.1年の平均在任期間)。